NLK as A Drug Target: Promises and Challenges (G51701)

Target Name: NLK

NCBI ID: G51701

Content of Review Report on NLK Target / Biomarker

NLK

NLK as A Drug Target: Promises and Challenges

NLK (NEO-L lymphokinase) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a key enzyme in the neurotransmitter kallikrein biosynthesis pathway, which is involved in the production of neurotransmitters such as serotonin, dopamine, and GABA.

The NLK gene has been identified as a potential drug target for the treatment of various psychiatric and neurological disorders, including depression, anxiety, and neurodegenerative diseases. This is because NLK is involved in the production of key neurotransmitters that are often impaired in these conditions, which can lead to the development of symptoms such as mood disorders, cognitive impairments, and motor symptoms.

In addition to its role in neurotransmitter production, NLK is also involved in the regulation of pain and inflammation. It has been shown to play a key role in the production of pain signals and in the regulation of the immune response to inflammation.

The potential uses of NLK as a drug target are vast. In addition to treating psychiatric and neurological disorders, NLK may also be used to treat other conditions such as pain, inflammation, and cancer.

One of the main advantages of NLK as a drug target is its widespread expression in various tissues. This makes it a promising candidate for use in a variety of different conditions. Additionally, NLK is well-characterized, which means that researchers have a good understanding of its biology and how it functions in different contexts.

Another advantage of NLK is its ability to modulate multiple signaling pathways. NLK has been shown to play a role in several signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. This makes it a versatile drug target and suggests that it may be effective in a wide range of different conditions.

The use of NLK as a drug target is still in its early stages, but it holds great promise for the treatment of a variety of different psychiatric and neurological disorders. Future research is likely to focus on understanding the full biology of NLK and developing new treatments that can modulate its activity.

Protein Name: Nemo Like Kinase

Functions: Serine/threonine-protein kinase that regulates a number of transcription factors with key roles in cell fate determination. Positive effector of the non-canonical Wnt signaling pathway, acting downstream of WNT5A, MAP3K7/TAK1 and HIPK2. Negative regulator of the canonical Wnt/beta-catenin signaling pathway. Binds to and phosphorylates TCF7L2/TCF4 and LEF1, promoting the dissociation of the TCF7L2/LEF1/beta-catenin complex from DNA, as well as the ubiquitination and subsequent proteolysis of LEF1. Together these effects inhibit the transcriptional activation of canonical Wnt/beta-catenin target genes. Negative regulator of the Notch signaling pathway. Binds to and phosphorylates NOTCH1, thereby preventing the formation of a transcriptionally active ternary complex of NOTCH1, RBPJ/RBPSUH and MAML1. Negative regulator of the MYB family of transcription factors. Phosphorylation of MYB leads to its subsequent proteolysis while phosphorylation of MYBL1 and MYBL2 inhibits their interaction with the coactivator CREBBP. Other transcription factors may also be inhibited by direct phosphorylation of CREBBP itself. Acts downstream of IL6 and MAP3K7/TAK1 to phosphorylate STAT3, which is in turn required for activation of NLK by MAP3K7/TAK1. Upon IL1B stimulus, cooperates with ATF5 to activate the transactivation activity of C/EBP subfamily members. Phosphorylates ATF5 but also stabilizes ATF5 protein levels in a kinase-independent manner (PubMed:25512613)

The "NLK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NLK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets